HLA-C and acute myeloid leukemia: Since the KIR2DL1/HLA-C*04 genotype seems to favor the escape of leukemic clones refractory to conventional and HSCT NK cell-based therapies, these children should be candidates for alternative treatments such as BiTe, CART, or experimental AML treatment.